STAT

Angered by high prices and shortages, hospitals will form their own generic drug maker

Four hospital systems are fighting back on high drug prices: They're forming a new, not-for-profit manufacturer of generic medicines.
Rising drug prices are drawing increased attention, including a congressional investigation into the hike from 5.6 cents to $3.65 a pill for an antibiotic called doxycycline hyclate.

Angered by rising prices and persistent shortages of generic drugs, four of the nation’s largest hospital systems are forming a new, not-for-profit manufacturer.

The new company plans to either directly make or subcontract manufacturing to combat “capricious and unfair pricing practices” that are damaging the generic drug market and hurting consumers, according to a statement from the four hospital groups — Intermountain Healthcare, Ascension, SSM Health, and Trinity Health, which together run more than 300 hospitals.

“It’s an ambitious plan,” said Dr. Marc Harrison, chief executive officer and president of Intermountain Healthcare, which is leading the initiative, “but healthcare systems are in the best position to fix the problems in the generic

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks